



University of Groningen

PET/MR imaging of neoplastic and inflammatory lesions

Catalano, Onofrio Antonio

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2018

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Catalano, O. A. (2018). PET/MR imaging of neoplastic and inflammatory lesions. [Groningen]: University of Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Chapter 1

Introduction

From: An overview of PET/MR, focused on clinical applications.

Catalano OA, Masch WR, Catana C, Mahmood U, Sahani DV, Gee MS, Menezes L, Soricelli A, Salvatore M, Gervais D, Rosen BR.
Abdom Radiol (NY). 2017;42(2):631-644

From: Nuclear Medicine Imaging in Pediatric Infection or Chronic Inflammatory Diseases.

Signore A, Glaudemans AWJM, Gheysens O, Lauri C, **Catalano OA**. *Semin Nucl Med*. 2017;47(3):286-303

From MR-PET of the body: Early experience and insights.

Ramalho M, AlObaidy M, **Catalano OA**, Guimaraes AR, Salvatore M, Semelka RC.
Eur J Radiol Open. 2014;1:28-39

From: Hybrid imaging in Crohn's disease: from SPECT/CT to PET/MR and new image interpretation criteria.

Catalano O, Maccioni F, Lauri C, Auletta S, **Signore A**.
Q J Nucl Med Mol Imaging. 2018;62(1):40-55.

Imaging inflammation and cancer by PET/MR

PET/MR is an innovative hybrid imaging technique that allows acquiring and fusing anatomical and functional data from magnetic resonance (MR) with metabolic information from positron emission tomography (PET) (1,2). MR and PET may be acquired simultaneously (co-acquisition) or sequentially (1,2). In the setting of co-acquisition, the MR and PET components simultaneously image the same body region. This allows for complete spatial and temporal matching of MR and PET data (1).

Development of PET/MR has recently advanced with innovations such as larger bore MR scanners, magnetic field insensitive avalanche photodiodes, and copper shielding (3).

Precise quantification of attenuation correction by PET/MR is challenging (3). A variety of methods such as Dixon-based tissue decomposition to atlas-based attenuation maps, to ultra-short echo time sequences (UTE), have helped but not completely resolved this issue (3–5).

PET/MR is the only hybrid imaging technology capable of co-acquisition of PET with morphologic imaging. This ensures temporal and spatial correlation of morphologic and functional data with one technique potentially complementing the other. In particular, PET quantification may be improved by MR anatomic information, which in turn may help *in vivo* validation of functional MR techniques (6). Moreover, MR-driven PET motion correction may reduce blurring and improve PET quantification in the case of patient motion, respiration, and bowel peristalsis (7).

PET/CT is the most accurate imaging technique for the staging of several solid organ neoplasms, with accuracy higher than CT or PET alone (8,9). PET detects metabolically active lesions and quantifies the amount of radiotracer uptake, expressed as standard uptake value (SUV), which might be helpful in evaluating treatment response (10,11). However, PET/CT is limited by the asynchronous acquisition of PET and CT, that induces potential miss-match between PET events and corresponding anatomic correlates, and by the intrinsically low soft tissue contrast of CT. Moreover, background physiologic radiotracer activity in conjunction with the low soft tissue resolution of CT can compromise detection of lesions with a low metabolic rate (for example some low-grade lymphomas) (12–19).

On the contrary, PET and MR data can be acquired simultaneously in PET/MR, with an ideal matching of the metabolic data of PET and the morphofunctional information of MR. This optimizes anatomic correlates for PET events and can produce unique hybrid biomarkers to potentially investigate lesion histology (for example discriminating inflammatory from fibrotic strictures in Crohn disease) or explore the molecular profile of cancer. Moreover, PET/MR provides superior soft tissue contrast to noise ratio and signal to noise ratio, which are fundamental in evaluating soft tissue pathology commonly encountered in abdominopelvic and breast imaging (1,12,20). MR is also capable of providing functional information, like diffusion weighted imaging (DWI) and the resultant apparent diffusion coefficient

(ADC) that may further enhance PET performance. Meanwhile, PET can improve the specificity of DWI and of ADC values.

The synergism of PET/MR, and the possibility to obtain unique hybrid functional metabolic biomarkers, that could potentially provide insights into tissue composition and molecular features of lesions, inspired us to investigate PET/MR in oncology and in Crohn's disease (CD).

Role of [¹⁸F]-FDG PET/CT in Crohn's disease

Several groups have evaluated the use of PET in Crohn disease (CD). Skehan *et al.* in 25 paediatric patients with suspected IBD, 15 of whom with CD, found that [¹⁸F]-FDG PET had an overall sensitivity of 81% and a specificity of 85%. Moreover, when colonoscopy was limited, PET localized further inflammatory areas in the proximal large bowel. Authors concluded that PET is a useful technique in children and it may be used as an adjunct to colonoscopy and barium studies when they are unsuccessful (21).

Several years later, the same group confirmed that PET identified active inflammatory disease in 81.5% of CD patients, according to endoscopic results. Therefore, although PET cannot replace conventional studies, it might be considered as an alternative technology in the appropriate clinical setting, keeping in mind the associated radiation exposure (22). Also, Loffler *et al.* performed FDG-PET in 23 paediatric patients, 17 of whom with CD, obtaining a sensitivity and specificity equal to 98% and 68% with histology as standard of reference, and 92% and 65% with endoscopy as standard of reference, respectively (23). They considered PET as a fast, non-invasive imaging method with low radiation exposure that allows the assessment of disease activity in children at an early stage.

Other authors evaluated the accuracy of FDG-PET to non-invasively assess inflammation in 43 CD patients, using ileocolonoscopy and magnetic resonance enterography (entero-MR) as reference standards. PET results were comparable to entero-MR for the assessment of the proximal ileum, and complementary to colonoscopy to assess the nature of strictures, suggesting PET as a promising non-

invasive technique for clinical management of CD (24). The same group compared PET to entero-MR and anti-granulocyte scintigraphy (GAB) in 59 patients with active CD. PET had the highest sensitivity (85%) followed by entero-MR (67%) and GAB (41%), while it demonstrated lower specificity (89%) than entero-MR (93%) and GAB (100%). Authors concluded that non-invasive detection of inflamed gut segments in CD with PET offers high sensitivity and specificity (25).

Berthold *et al.* (26) compared PET versus PET/CT in 23 children and adolescents, 19 of whom with CD, using endoscopy with biopsy and histology as gold standard. The authors demonstrated that, although CT provided additional anatomical information, only PET was able to locate the active disease in the gut segments. Moreover, PET detected extra intestinal inflammation, and allowed the assessment of the extent and degree of high-grade inflammation, especially in those small bowel segments that were not accessible to endoscopy. Several authors have investigated whether CT provides better anatomical details, improving the diagnostic accuracy of PET, for the assessment of inflammation in adult and paediatric patients with CD. Bettenworth *et al.* (27) performed PET/CT in 25 patients with histologically diagnosed Crohn's colitis. PET/CT was positive in 88% of extensive ulcerations, but only in 50% of superficial epithelial lesions. The author concluded that PET/CT is a non-invasive and promising translational method. Moreover, they found that the intestinal glucose uptake is variable and pathologic segments might be difficult to distinguish from normal ones. The same group compared [¹⁸F]-FDG PET/CT, entero-MR and trans-abdominal ultrasound in order to evaluate the best non-invasive imaging method for the detection and differentiation of inflammatory and fibromatous stenoses in CD, using endoscopy and histology as reference standards. A combination of trans-abdominal ultrasound and PET/CT or entero-MR led to a 100% detection rate (28). Jacene *et al.* (29) preoperatively investigated the accuracy of PET/CT in CD patient with obstructive symptoms in comparison to postoperative histopathological analyses of these lesions. In their study, different lesions demonstrated FDG uptake, including inflammatory lesions, fibrotic strictures and muscle hypertrophy. The authors suggested that, although a qualitative PET analysis is sensitive, a semi-quantitative

analysis could help identifying patients with active inflammation, using the maximum lean standardized uptake value (SUL_{max}). Another group studied the clinical utility of PET/CT in 7 patients, 4 of whom with CD, and showed that PET/CT can be viewed as a useful imaging method in diagnosis, management and clinical decision-making of patients with known or suspected CD (30). Louis and colleagues in a prospective study, which included 22 patients with active CD, found that PET/CT detected 35 of 48 endoscopically affected segments, with a sensitivity and a specificity of 72.9% and 55.3%, respectively. Furthermore, severe endoscopic lesions, such as deep ulcers and strictures, were detected by PET/CT with a sensitivity of 100%, suggesting a direct correlation between PET sensitivity and clinical significance. Overall, PET/CT scores correlated with clinical parameters, endoscopy and biological activity of CD (31). Meisner *et al.* conducted another study using PET/CT for the assessment of disease activity in 12 patients with IBD, 7 of whom with CD. In their study, PET/CT was positive in 59.4% of segments and there was 81.3% correlation between PET activity and clinical activity, demonstrating utility of PET as a non-invasive technique to identify active inflammatory regions in CD (32). The feasibility and potential clinical utility of [^{18}F]-FDG PET/CT for the assessment of CD activity was also investigated in a study performed by Saboury *et al.* in which 22 subjects underwent PET/CT followed by ileocolonoscopy in order to correlate imaging results with clinical and endoscopic findings. PET/CT detected 15 additional segments compared to those visualized by endoscopy and all global PET parameters correlated with standard clinical scores (CDAI), allowing a new quantitative analysis of regional and global CD activity using PET imaging (33). Recently, Russo and colleagues evaluated the role of [^{18}F]-FDG PET/CT as a marker of progression of inflammatory activity and its response to anti-TNF therapy in 22 patients with CD. PET/CT sensitivity and specificity were respectively 88% and 70%; moreover, SUV correlated with clinicopathological markers like C-reactive protein and Harvey-Bradshaw Index (34).

Other authors studied the CD activity combining [^{18}F]-FDG PET with CT enteroclysis or CT enterography. Das *et al.* included in a prospective study 17 patients, 9 of whom with CD, using PET/CT enteroclysis in order to obtain both

morphological and functional details. PET/CT enteroclysis outperformed barium studies and colonoscopy in detecting affected segments in the small and large bowel (50 versus 16 versus 17 segments respectively). Furthermore, PET/CT enteroclysis detected also extra-intestinal abnormalities and differentiated active from fibrostenotic CD (35). Ahmadi and colleagues examined the role of combined [¹⁸F]-FDG PET/CT enterography (CTe) in active CD. CTe identified 48 abnormal small bowel segments as well as PET. The authors also found a correlation between CTe score and SUV_{max}, suggesting a similar sensitivity of both imaging methods; moreover, PET provided additional information quantifying the degree of inflammation in abnormal small bowel segments (36).

Groshar *et al.* performed [¹⁸F]-FDG PET/CTe in 28 patients with known or suspected CD in order to correlate the CTe score and SUV_{max} for the assessment of the grade and severity of inflammation in abnormal segments. They detected 85 abnormal segments in 22 patients, with a good correlation between SUV_{max} and CTe measurements of mural thickness and enhancement, concluding that SUV_{max} might be a reliable parameter to quantify CD activity (37).

Finally, Shyn *et al.* compared [¹⁸F]-FDG PET/CTe with CTe alone with the purpose of evaluating the diagnostic efficacy of the two imaging methods in 13 patients with CD. Different parameters such as CTe severity score, SUV_{max}, simplified endoscopic score, and clinical parameters correlated with pathology inflammation grade. In 3 patients, PET detected active inflammation and an enterocolonic fistula, not revealed by CTe alone. SUV_{max} strongly correlated with disease activity, suggesting that PET/CTe might improve the detection and grading of active inflammation in CD patients (38).

PET/MR in IBD: advantages and disadvantages

Hybrid PET/MR scanners are the most advanced, clinically approved devices available for in-vivo diagnostic imaging. They can simultaneously (co-acquisition)

or sequentially acquire metabolic data from positron emission tomography (PET) as well as functional and morphologic information from magnetic resonance (MR) (1,2).

In the setting of co-acquisition, the PET and MR components of this hybrid technology simultaneously image the same body region, allowing a nearly complete spatial and temporal matching of PET and MR data. This spatial and temporal matching is not achievable by sequential PET/MR scanners neither by PET/CT, with the latter being limited by the necessarily asynchronous acquisition of the PET events and the CT data (1). The matching of the PET and MR data translates into the possibility of exploring a queried lesion, for example a thickened bowel loop, with a large array of PET and functional MR (fMR) biomarkers that include, among others, SUVmax, metabolic volume (MV), apparent diffusion coefficient (ADC), and volume transfer coefficient (Ktrans). This would be precluded, due to bowel peristalsis and patient movements, in the case of sequentially acquired PET and MR scans.

Secondarily PET/MR co-acquisition may symbiotically overcome some limitations of each modality taken apart (6). Moreover, serially acquired high temporal resolution MR data can track and quantitate patient and bowel motion allowing for MR-assisted PET motion correction with subsequent reduction in PET related motion artifacts, noise, blurring, and increased contrast (6,7).

Another important advantage of PET/MR compared to PET/CT is the reduced radiation burden to the patient. PET/MR allows a 20% reduction in radiation exposure compared to PET/CT, when the CT component is used for attenuation correction only, or up to 60-73% if the CT part is employed both for attenuation correction and for producing diagnostic quality CT images (39,40).

The geometry of the PET components of the PET/MR scanners, with the resultant increased sensitivity in the center of the PET field of view (FOV), allows reducing activity to up to 30-50% of that required for comparable quality PET from PET/CT (41).

Moreover, the lengthier times required to acquire MR sequences might be used to prolong PET acquisition, improving the quality of the PET images and/or allowing a

lower activity. In a phantom study, increasing bed position time by a factor of 8, from 2 minutes to 16 minutes, allowed reducing to 1/8 (12.5%) the injected activity, with PET images displaying same signal to contrast ratio as those obtained from 100% activity while using 2 minutes per bed position (42).

This is extremely important in CD patients who are usually younger at presentation and will likely require several follow-up studies in the course of their disease.

A major disadvantage of PET/MR compared to PET/CT relies in its limits in quantifying the attenuation exerted by body tissues on the gamma-rays. While in PET/CT the density of the tissues, as measured by CT Hounsfield units, may be used to compute the linear attenuation correction (LAC), this is not the case of PET/MR where the signal intensity of the tissue does not have any direct relations with the LAC. Several techniques have been employed to address this issue, the most effective being tissue segmentation/decomposition and atlas based methods. However, this problem has not been resolved completely. But new approaches based on artificial intelligence seem very promising.

Another potential disadvantage of PET/MR, compared to PET/CT, is the lengthier acquisition time (23-30 minutes for a Crohn's PET/MR protocol versus 12-15 minutes for a Crohn's PET/CT study), with MR acquisition being the time limiting factor. However, neither PET nor MR quality should be compromised if intention is to maximize clinical benefit from PET/MR capabilities.

Most of the research efforts in clinical PET/MR have been deployed in neurologic and oncologic imaging. In selected indications, PET/MR has been proven advantageous over PET/CT, and also over PET and MR performed separately. For example, PET/MR improves staging of central nervous system cancers, detection of satellite brain lesions, residual disease, and evaluation of intratumoral heterogeneity (43–47).

In oncologic body imaging PET/MR has been demonstrated to be superior to PET/CT and also to MR in several respects, including evaluation of liver, peritoneal, bone, and lymph node metastases, and whole-body staging of different primary cancers. Moreover, PET/MR can also provide insights into the tumor biology, as in the case of breast cancer (48–57).

PET/MR has enormous potentialities also in the evaluation of Crohn's disease. However, it has been rarely used in this disease, with only two research manuscripts available in the literature (25,31,58-60).

PET/MR might increase the diagnostic confidence in assessing patients affected by Crohn's disease. It has been shown that MR enterography, PET/CT enterography, and PET/MR enterography had similar accuracy in detecting areas affected by Crohn's disease. However PET/MR enterography provided additional clinically relevant information due to its increased accuracy in assessing extra-luminal manifestations of the disease, that were associated with higher need for stoma [$p = 0.022$], and also distant localization [$p = 0.002$] (59).

PET/MR enterography was also useful in assessing the dominant nature of strictures. Strictures constitute one of the most important clinical challenges in Crohn's disease. They occur in about 11% of patients at presentation, and their prevalence increases over time. Moreover, they represent a major cause of morbidity in Crohn's disease (28,61,62).

While several medical options are available for predominantly inflammatory strictures, the fibrotic ones need to be treated more invasively, by surgery or mechanical dilatation. This pivotal information, however, is not usually available to the clinicians, due to the limits of current techniques, even in the case of endoscopic biopsy. Therefore patients are usually treated conservatively first, and in the case of failure, a surgical approach is pursued (28,61,62).

In two very recent PET/MR studies focused on this very specific topic, with surgical pathology as standard of reference, it was found that PET/MR could be useful to differentiate between fibrotic and inflammatory strictures.

PET/MR enterography was more accurate in detecting fibrosis compared with PET/CT enterography [$p = 0.043$] and with MR enterography [$p = 0.024$] (59).

Among the different PET/MR biomarkers that were investigated, the best discriminator between fibrosis and active inflammation was the hybrid PET/MR enterography biomarker $ADC * SUV_{max}$, that at a cutoff of less than 3000, was associated with accuracy, sensitivity, and specificity of 71%, 67%, and 73%, respectively for purely fibrotic strictures (60).

PET/MR in neoplastic patients: advantages and disadvantages

PET/MR has several potential advantages over PET/CT and over MR and PET standing alone in oncologic imaging. The simultaneous acquisition of PET and MR data allows for complete spatial and temporal matching of MR and PET data and makes it possible to compensate for motion both MR and PET data. This translates into the possibility to improve image quality, increase detection rate, provide more precise quantitative assessment of lesion pharmacokinetics and metabolism (1,58). Moreover, the high signal to noise and contrast to noise ratios of MR, and the resultant high quality anatomic layout, allow to better localize areas of abnormal metabolism detected by PET, especially in critical areas, like the subcapsular liver parenchyma and the pelvis, and to pin point lesions that, because of small size or critical location or high background activity or low intrinsic metabolism, might be missed by PET alone (58). This can be advantageous in improving clinical staging and restaging, ascertaining the benign or malignant nature of lesions, providing an anatomic-metabolic road map to the surgeons, and investigate the biology of cancers (57,58).

PET and MR together may play a pivotal role in several oncologic entities, complementing each other. One of this field might be neuro-oncology. Contrast enhanced MR, by itself, is the method of choice for the initial evaluation and follow up of brain tumors. However, contrast enhancement of lesions is imperfect being influenced by several factors related to tumor biology, e.g. blood flow and vessel permeability, and to brain physiology, e.g., the blood-brain barrier. Therefore, reduction of lesion enhancement after therapy does not always correlate with tumor response. Although PET can rely on specific tracers exploring selective features of tumor biology, like amino acid transport (^{11}C -methionine and ^{18}F -fluoroethyltyrosine), hypoxia (^{18}F -fluoromisonidazole), and proliferation (^{18}F -fluoroethylthymidine), it is influenced by blood perfusion to the affected areas and by local permeability. For example, MR can help PET to discriminate the transport and metabolic trapping of ^{18}F -fluoroethylthymidine allowing a better quantification

of tumor cell proliferation. It is expected that PET/MR can overcome the limitations of each technique when used separately (6). PET/MR may prove useful for a more accurate pre-surgical planning showing the relationships of the metabolic vital portions of brain tumors with adjacent white matter tracts, infiltration and displacement. Moreover, it is capable of highlighting functionally important areas that need to be spared such as Broca's area. It has already been demonstrated that PET/MR can change the radiation target volume when compared to stand alone MR or PET (63).

In the field of body oncology, PET/CT represents the gold standard technique for the staging of several solid organ neoplasms and it has been shown to allow a more accurate TNM staging than CT or PET alone (8,9). PET can detect metabolically active lesions and quantify the amount of radiotracer uptake, expressed as standard uptake value (SUV), with several cut off values proposed to discriminate malignant from benign lesions. Quantification of radiotracer uptake has also been shown helpful in assessing treatment response by following changes in lesion metabolism (10,11). Despite its attributes, PET/CT has limitations imposed by the low intrinsic soft tissue contrast of CT, and by physiologic radiotracer uptake in normal tissues that may render lesions with a low metabolic rate (e.g, well-differentiated hepatocellular carcinoma, mucinous adenocarcinomas, neuroendocrine tumors, and some low-grade lymphomas) difficult to detect. Neoplastic lesions in or adjacent to tissues with normally high metabolism (e.g., liver, kidneys) may be overlooked (12–19).

PET/MR couples the advantages of PET with the superior soft tissue contrast of MR allowing for the improved assessment of fine anatomical detail, and the clear depiction of lesion margins, local tumor infiltration, and the relationship of lesions to adjacent structures. One such application can be in evaluating extension of rectal cancers beyond the tunica muscularis and threatening of the mesorectal fascia that might be very hard to assess by PET/CT, unless extensive (1,12,20). Moreover, MR is also capable of providing functional information with diffusion weighted imaging (DWI), perfusion imaging, and spectroscopy which may be used for lesion detection and characterization.

DWI is particularly valuable in the assessment of lesion cellularity, and may be used as a whole-body screening technique for the detection of hyper-cellular neoplasms, including lesions less than 10mm in diameter (64,65). DWI greatly contributes to the sensitivity of PET/MR. In our experience it is equivalent to PET in identifying neoplastic metabolically active lesions and is superior to PET in identifying neoplastic lesions with low metabolic activity. While highly sensitive, DWI suffers from low specificity. Lesions detected at DWI may be better characterized with a combination of morpho-functional MR criteria and metabolic PET criteria leading to increased specificity and improved readers' confidence. These include similarity of signal intensity of the lesion with that of the primary neoplasm, areas of internal necrosis as on T2 weighted and on contrast enhanced images, apparent diffusion coefficient (ADC) values $<1.4 \times 10^{-3} \text{mm}^2/\text{s}$ for distant metastases and $<1.0 \times 10^{-3} \text{mm}^2/\text{s}$ for lymphadenopathy (66–68), $\text{SUV} \geq 2.5$ (10,11); satisfaction of these criteria allows to call a lesion as malignant (10,11,66–69). In our experience, the superior ability of PET/MR to characterize subcentimeter lesions as benign or malignant allows for increased staging accuracy over other modalities.

PET/CT may detect small foci of radionuclide uptake due to the PET component. However, due to the low soft tissue contrast of CT and the sequential nature of data acquisition inherent to PET/CT, lesion localization may suffer in some circumstances, and anatomic correlates for small PET findings may be overlooked. Conversely, concurrent data acquisition with PET/MR allows each modality to help the other in an additive manner. PET/MR will often help detecting small lesions that may be ignored by either modality alone. Specific instances include small peritoneal lesions that may be missed by MR or miss-interpreted by FDG-PET as non-specific intestinal uptake (e.g., small foci of carcinomatosis in the supramesocolic region) (70–72). In our experience, PET/MR is particularly helpful in evaluating lymph node, liver, bone, pelvic organ, and breast.

Size criteria are often used to differentiate benign from malignant lymph nodes on both MR and CT, with a short axis diameter of $\geq 10\text{mm}$ being a common threshold for malignancy (73). However, this method suffers from both low sensitivity and specificity as non-neoplastic conditions may result in “pathologic” lymph node

enlargement and small lymph nodes may harbor metastatic disease. In the setting of rectal cancer, up to 15% of pelvic lymph nodes less than 5mm are metastatic (69,74). MR-based morpho-functional indices, including lymph node T2-weighted characteristics, internal structure, shape, margin, and ADC value (ADC $<1.0 \times 10^{-3}$ mm²/s suggesting malignancy), combined with metabolic PET data account for good performance figures of PET/MR in the assessment of lymph nodes below the 10mm threshold.

PET/MR is an ideal technique for oncologic liver imaging. MR alone, given its exquisite soft tissue resolution, is superior to CT alone in evaluating the liver parenchyma. PET improves the assessment of critical regions adjacent to the liver capsule and intrahepatic vasculature. Moreover PET facilitates the evaluation of areas that have undergone local regional therapies (e.g. TACE, thermal ablation, and SIRT) (75–77). Moreover, PET/MR value is not hampered by coexisting hepatic steatosis, a common limitation of CT in the setting of chemotherapy.

Sclerotic bone metastases are readily detected by CT, however, subtle lytic metastases, particularly those lacking cortical breakthrough, are often overlooked. The sensitivity of CT for the detection of bone metastases is further reduced in patients with osteopenia. FDG-PET will often identify pathologic FDG uptake in bone prior to the development of an anatomic CT correlate. PET/CT evaluation of bone is often confounded in the setting of increased hematopoietic bone marrow uptake from chemotherapy or colony stimulating factor administration, and is not sensitive in the detection of hypometabolic metastases (78–80). Specific radiotracers, such as ¹⁸F-Fluoride, may be used to improve PET detection of bony metastases (81,82). PET/MR with FDG may identify subtle signal alterations on MR that provide anatomic correlates for otherwise indeterminate foci of FDG avidity, improving confidence in the diagnosis of bone metastases. STIR and DWI are sensitive for bone marrow edema; T1weighted imaging, including pre and post contrast imaging, is sensitive for sclerotic metastases as well as marrow replacing. In a comparative study it has been shown that whole body MR outperforms bone scintigraphy and targeted x-rays, being more sensitive for bone metastases from prostate cancer (sensitivity of 98-100% versus 86% respectively). However whole

body MR had similar specificity (specificity of 98-100% versus 98% respectively)(83).

PET/MR has the potential to greatly improve the care of patients with pelvic cancers, a rather common entity. For most pelvic cancers, accurate local staging is important for treatment planning. PET/CT imaging is limited in local staging due to the low soft tissue contrast and the presence of excreted radiotracer in the bladder that limits assessment of adjacent structures (84). MR alone is also limited, given the potentiality for metastatic disease in lymph nodes <10mm. PET/MR combines the improved T staging inherent to MR with the improved N staging of PET (85,86). Furthermore, the low sensitivity of MR for the detection of small peritoneal implants and recurrent/residual disease after treatment may be improved in the presence of concurrent PET data (84–87). From our initial clinical and research activities, we feel that PET/MR will prove superior to MR or PET alone in both initial staging of pelvic cancers and post treatment surveillance.

In our experience, PET/MR is extremely useful for breast cancer staging and follow up. The coacquisition of contrast enhanced MR and PET improves characterization of subcentimeter foci of non-mass like enhancement and improves the sensitivity for the detection of synchronous lesions.

Several factors have the potential to hamper PET/MR performance. These are often related to the MR component of PET/MR. They include issues with lesion localization due to motion artifact (particularly in the region of the diaphragm, heart and bowel), and issues with image degradation due to magnetic susceptibility artifacts. PET/MR requires appropriate patient cooperation and is longer than PET/CT (average length 50-80 minutes according to the protocols). For patients unable to perform breath holds or hold still, PET/CT is preferred.

Compared to CT, MR has lower temporal and spatial resolution, making PET/MR challenging in the setting of lung nodules less than 6mm in diameter. However, Stolzman *et al.* (88), using a trimodality scanner to evaluate lung nodules on CT, MR, and PET, both separately and in various combinations, found similar detection rates for lung nodules on PET/MR (83%) and PET/CT (85%). These results are in keeping with a comparative study of PET/MR and PET/CT which showed that

PET/MR did not miss clinically relevant lung nodules in 134 consecutive oncologic patients (55).

According to our preliminary clinical experience, PET/MR is not inferior to PET/CT in lung assessment and outperforms PET/CT in the detection and characterization of lymph nodes, bone metastases, and liver metastases, and in the staging of pelvic malignancies. Moreover, PET/MR can evaluate tumor regions such as the kidneys that are difficult to assess by PET/CT. PET/MT can also detect additional coexistent incidental neoplasms in the kidneys and breasts, not identified on PET/CT.

Finally PET/MR suffers of the same contraindications as per MR only, including claustrophobia, metallic foreign bodies, ferromagnetic implants and devices. Moreover, because it is a relatively novel technology, there are no consolidated clinical protocols for PET/MR.

References

1. Delso G, Fürst S, Jakoby B, Ladebeck R, Ganter C, Nekolla SG, et al. Performance measurements of the Siemens mMR integrated whole-body PET/MR scanner. *J Nucl Med*. 2011 Dec;52(12):1914–22.
2. Zaidi H, Ojha N, Morich M, Griesmer J, Hu Z, Maniawski P, et al. Design and performance evaluation of a whole-body Ingenuity TF PET-MRI system. *Phys Med Biol*. 2011 May 21;56(10):3091–106.
3. Catana C, Guimaraes AR, Rosen BR. PET and MR imaging: the odd couple or a match made in heaven? *J Nucl Med*. 2013 May;54(5):815–24.
4. Hofmann M, Bezrukov I, Mantlik F, Aschoff P, Steinke F, Beyer T, et al. MRI-based attenuation correction for whole-body PET/MRI: quantitative evaluation of segmentation- and atlas-based methods. *J Nucl Med*. 2011 Sep;52(9):1392–9.
5. Dickson JC, O'Meara C, Barnes A. A comparison of CT- and MR-based attenuation correction in neurological PET. *Eur J Nucl Med Mol Imaging*. 2014 Jun;41(6):1176–89.
6. Catana C, Drzezga A, Heiss W-D, Rosen BR. PET/MRI for neurologic applications. *J Nucl Med*. 2012 Dec;53(12):1916–25.
7. Catana C. Motion correction options in PET/MRI. *Semin Nucl Med*. 2015 May;45(3):212–23.
8. Antoch G, Stattaus J, Nemat AT, Marnitz S, Beyer T, Kuehl H, et al. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. *Radiology*. 2003 Nov;229(2):526–33.
9. Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. *N Engl J Med*. 2003 Jun 19;348(25):2500–7.
10. Boss DS, Olmos RV, Sinaasappel M, Beijnen JH, Schellens JHM. Application of PET/CT in the development of novel anticancer drugs. *Oncologist*. 2008 Jan;13(1):25–38.
11. Al-Sugair A, Coleman RE. Applications of PET in lung cancer. *Semin Nucl Med*. 1998 Oct;28(4):303–19.
12. Torigian DA, Zaidi H, Kwee TC, Saboury B, Udupa JK, Cho Z-H, et al. PET/MR imaging: technical aspects and potential clinical applications. *Radiology*. 2013 Apr;267(1):26–44.
13. Jerusalem G, Beguin Y, Najjar F, Hustinx R, Fassotte MF, Rigo P, et al. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). *Ann Oncol*. 2001 Jun;12(6):825–30.
14. Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, et al. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. *Cancer*. 2008 Jun;112(11):2447–55.
15. Park J-W, Kim JH, Kim SK, Kang KW, Park KW, Choi J-I, et al. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. *J Nucl Med*. 2008 Dec;49(12):1912–21.

16. Son H, Khan SM, Rahaman J, Cameron KL, Prasad-Hayes M, Chuang L, et al. Role of FDG PET/CT in staging of recurrent ovarian cancer. *Radiographics*. 2011 Apr;31(2):569–83.
17. Mueller-Lisse UG, Mueller-Lisse UL, Meindl T, Coppenrath E, Degenhart C, Graser A, et al. Staging of renal cell carcinoma. *Eur Radiol*. 2007 Sep;17(9):2268–77.
18. Ozawa Y, Hara M, Sakurai K, Nakagawa M, Tamaki T, Nishio M, et al. Diagnostic accuracy of (18)F-2-deoxy-fluoro-D-glucose positron emission tomography for pN2 lymph nodes in patients with lung cancer. *Acta Radiol*. 2010 Mar;51(2):150–5.
19. Sharma P, Kumar R, Singh H, Jeph S, Sharma DN, Bal C, et al. Carcinoma endometrium: role of 18-FDG PET/CT for detection of suspected recurrence. *Clin Nucl Med*. 2012 Jul;37(7):649–55.
20. von Schulthess GK, Schlemmer H-PW. A look ahead: PET/MR versus PET/CT. *Eur J Nucl Med Mol Imaging*. 2009 Mar;36 Suppl 1:S3-9.
21. Skehan SJ, Issenman R, Mernagh J, Nahmias C, Jacobson K. 18F-fluorodeoxyglucose positron tomography in diagnosis of paediatric inflammatory bowel disease. *Lancet*. 1999 Sep 4;354(9181):836–7.
22. Lemberg DA, Issenman RM, Cawdron R, Green T, Mernagh J, Skehan SJ, et al. Positron emission tomography in the investigation of pediatric inflammatory bowel disease. *Inflamm Bowel Dis*. 2005 Aug;11(8):733–8.
23. Löffler M, Weckesser M, Franzius C, Schober O, Zimmer KP. High diagnostic value of 18F-FDG-PET in pediatric patients with chronic inflammatory bowel disease. *Ann N Y Acad Sci*. 2006 Aug;1072:379–85.
24. Holtmann MH, Uenzen M, Helisch A, Dahmen A, Mudter J, Goetz M, et al. 18F-Fluorodeoxyglucose positron-emission tomography (PET) can be used to assess inflammation non-invasively in Crohn's disease. *Dig Dis Sci*. 2012 Oct;57(10):2658–68.
25. Neurath MF, Vehling D, Schunk K, Holtmann M, Brockmann H, Helisch A, et al. Noninvasive assessment of Crohn's disease activity: a comparison of 18F-fluorodeoxyglucose positron emission tomography, hydromagnetic resonance imaging, and granulocyte scintigraphy with labeled antibodies. *Am J Gastroenterol*. 2002 Aug;97(8):1978–85.
26. Berthold LD, Steiner D, Scholz D, Alzen G, Zimmer KP. Imaging of chronic inflammatory bowel disease with 18F-FDG PET in children and adolescents. *Klin Padiatr*. 2013 Jul;225(4):212–7.
27. Bettenworth D, Reuter S, Hermann S, Weckesser M, Kerstiens L, Stratis A, et al. Translational 18F-FDG PET/CT imaging to monitor lesion activity in intestinal inflammation. *J Nucl Med*. 2013 May;54(5):748–55.
28. Lenze F, Wessling J, Bremer J, Ullerich H, Spieker T, Weckesser M, et al. Detection and differentiation of inflammatory versus fibromatous Crohn's disease strictures: prospective comparison of 18F-FDG-PET/CT, MR-enteroclysis, and transabdominal ultrasound versus endoscopic/histologic evaluation. *Inflamm Bowel Dis*. 2012 Dec;18(12):2252–60.

29. Jacene HA, Ginsburg P, Kwon J, Nguyen GC, Montgomery EA, Bayless TM, et al. Prediction of the need for surgical intervention in obstructive Crohn's disease by 18F-FDG PET/CT. *J Nucl Med*. 2009 Nov;50(11):1751–9.
30. Lapp RT, Spier BJ, Perlman SB, Jaskowiak CJ, Reichelderfer M. Clinical utility of positron emission tomography/computed tomography in inflammatory bowel disease. *Mol Imaging Biol*. 2011 Jun;13(3):573–6.
31. Louis E, Ancion G, Colard A, Spote V, Belaiche J, Hustinx R. Noninvasive assessment of Crohn's disease intestinal lesions with (18)F-FDG PET/CT. *J Nucl Med*. 2007 Jul;48(7):1053–9.
32. Meisner RS, Spier BJ, Einarsson S, Roberson EN, Perlman SB, Bianco JA, et al. Pilot study using PET/CT as a novel, noninvasive assessment of disease activity in inflammatory bowel disease. *Inflamm Bowel Dis*. 2007 Aug;13(8):993–1000.
33. Saboury B, Salavati A, Brothers A, Basu S, Kwee TC, Lam MGEH, et al. FDG PET/CT in Crohn's disease: correlation of quantitative FDG PET/CT parameters with clinical and endoscopic surrogate markers of disease activity. *Eur J Nucl Med Mol Imaging*. 2014 Apr;41(4):605–14.
34. Russo EA, Khan S, Janisch R, Gunn RN, Rabiner EA, Taylor SA, et al. Role of 18F-fluorodeoxyglucose Positron Emission Tomography in the Monitoring of Inflammatory Activity in Crohn's Disease. *Inflamm Bowel Dis*. 2016 Nov;22(11):2619–29.
35. Das CJ, Makharia G, Kumar R, Chawla M, Goswami P, Sharma R, et al. PET-CT enteroclysis: a new technique for evaluation of inflammatory diseases of the intestine. *Eur J Nucl Med Mol Imaging*. 2007 Dec;34(12):2106–14.
36. Ahmadi A, Li Q, Muller K, Collins D, Valentine JF, Drane W, et al. Diagnostic value of noninvasive combined fluorine-18 labeled fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography enterography in active Crohn's disease. *Inflamm Bowel Dis*. 2010 Jun;16(6):974–81.
37. Groshar D, Bernstine H, Stern D, Sosna J, Eligalashvili M, Gurbuz EG, et al. PET/CT enterography in Crohn disease: correlation of disease activity on CT enterography with 18F-FDG uptake. *J Nucl Med*. 2010 Jul;51(7):1009–14.
38. Shyn PB, Mortelet KJ, Britz-Cunningham SH, Friedman S, Odze RD, Burakoff R, et al. Low-dose 18F-FDG PET/CT enterography: improving on CT enterography assessment of patients with Crohn disease. *J Nucl Med*. 2010 Dec;51(12):1841–8.
39. Schäfer JF, Gatidis S, Schmidt H, Gückel B, Bezrukov I, Pfannenberger CA, et al. Simultaneous whole-body PET/MR imaging in comparison to PET/CT in pediatric oncology: initial results. *Radiology*. 2014 Oct;273(1):220–31.
40. Atkinson W, Catana C, Abramson JS, Arabasz G, McDermott S, Catalano O, et al. Hybrid FDG-PET/MR compared to FDG-PET/CT in adult lymphoma patients. *Abdom Radiol (NY)*. 2016 Jul;41(7):1338–48.
41. Queiroz MA, Delso G, Wollenweber S, Deller T, Zeimpekis K, Huellner M, et al. Dose Optimization in TOF-PET/MR Compared to TOF-PET/CT. *PLoS ONE*. 2015 Jul 6;10(7):e0128842.
42. Oehmigen M, Ziegler S, Jakoby BW, Georgi J-C, Paulus DH, Quick HH. Radiotracer dose reduction in integrated PET/MR: implications from national

- electrical manufacturers association phantom studies. *J Nucl Med*. 2014 Aug;55(8):1361–7.
43. Kjær A, Loft A, Law I, Berthelsen AK, Borgwardt L, Löfgren J, et al. PET/MRI in cancer patients: first experiences and vision from Copenhagen. *MAGMA*. 2013 Feb;26(1):37–47.
 44. Pichler BJ, Kolb A, Nägele T, Schlemmer H-P. PET/MRI: paving the way for the next generation of clinical multimodality imaging applications. *J Nucl Med*. 2010 Mar;51(3):333–6.
 45. Boss A, Bisdas S, Kolb A, Hofmann M, Ernemann U, Claussen CD, et al. Hybrid PET/MRI of intracranial masses: initial experiences and comparison to PET/CT. *J Nucl Med*. 2010 Aug;51(8):1198–205.
 46. Navarria P, Reggiori G, Pessina F, Ascolese AM, Tomatis S, Mancosu P, et al. Investigation on the role of integrated PET/MRI for target volume definition and radiotherapy planning in patients with high grade glioma. *Radiother Oncol*. 2014 Sep;112(3):425–9.
 47. Preuss M, Werner P, Barthel H, Nestler U, Christiansen H, Hirsch FW, et al. Integrated PET/MRI for planning navigated biopsies in pediatric brain tumors. *Childs Nerv Syst*. 2014 Aug;30(8):1399–403.
 48. Lee DH, Lee JM, Hur BY, Joo I, Yi N-J, Suh K-S, et al. Colorectal cancer liver metastases: diagnostic performance and prognostic value of PET/MR imaging. *Radiology*. 2016 Sep;280(3):782–92.
 49. Kang B, Lee JM, Song YS, Woo S, Hur BY, Jeon JH, et al. Added Value of Integrated Whole-Body PET/MRI for Evaluation of Colorectal Cancer: Comparison With Contrast-Enhanced MDCT. *AJR Am J Roentgenol*. 2016 Jan;206(1):W10-20.
 50. Reiner CS, Stolzmann P, Husmann L, Burger IA, Hüllner MW, Schaefer NG, et al. Protocol requirements and diagnostic value of PET/MR imaging for liver metastasis detection. *Eur J Nucl Med Mol Imaging*. 2014 Apr;41(4):649–58.
 51. Lee G, I H, Kim S-J, Jeong YJ, Kim IJ, Pak K, et al. Clinical implication of PET/MR imaging in preoperative esophageal cancer staging: comparison with PET/CT, endoscopic ultrasonography, and CT. *J Nucl Med*. 2014 Aug;55(8):1242–7.
 52. Catalano OA, Nicolai E, Rosen BR, Luongo A, Catalano M, Iannace C, et al. Comparison of CE-FDG-PET/CT with CE-FDG-PET/MR in the evaluation of osseous metastases in breast cancer patients. *Br J Cancer*. 2015 Apr 28;112(9):1452–60.
 53. Samarin A, Hüllner M, Queiroz MA, Stolzmann P, Burger IA, von Schulthess G, et al. 18F-FDG-PET/MR increases diagnostic confidence in detection of bone metastases compared with 18F-FDG-PET/CT. *Nucl Med Commun*. 2015 Dec;36(12):1165–73.
 54. Eiber M, Takei T, Souvatzoglou M, Mayerhoefer ME, Fürst S, Gaertner FC, et al. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions. *J Nucl Med*. 2014 Feb;55(2):191–7.
 55. Catalano OA, Rosen BR, Sahani DV, Hahn PF, Guimaraes AR, Vangel MG, et al. Clinical impact of PET/MR imaging in patients with cancer undergoing

- same-day PET/CT: initial experience in 134 patients--a hypothesis-generating exploratory study. *Radiology*. 2013 Dec;269(3):857–69.
56. Catalano OA, Coutinho AM, Sahani DV, Vangel MG, Gee MS, Hahn PF, et al. Colorectal cancer staging: comparison of whole-body PET/CT and PET/MR. *Abdom Radiol (NY)*. 2017 Apr;42(4):1141–51.
 57. Catalano OA, Horn GL, Signore A, Iannace C, Lepore M, Vangel M, et al. PET/MR in invasive ductal breast cancer: correlation between imaging markers and histological phenotype. *Br J Cancer*. 2017 Mar 28;116(7):893–902.
 58. Catalano OA, Masch WR, Catana C, Mahmood U, Sahani DV, Gee MS, et al. An overview of PET/MR, focused on clinical applications. *Abdom Radiol (NY)*. 2017 Feb;42(2):631–44.
 59. Pellino G, Nicolai E, Catalano OA, Campione S, D'Armiento FP, Salvatore M, et al. PET/MR Versus PET/CT Imaging: Impact on the Clinical Management of Small-Bowel Crohn's Disease. *J Crohns Colitis*. 2016 Mar;10(3):277–85.
 60. Catalano OA, Gee MS, Nicolai E, Selvaggi F, Pellino G, Cuocolo A, et al. Evaluation of Quantitative PET/MR Enterography Biomarkers for Discrimination of Inflammatory Strictures from Fibrotic Strictures in Crohn Disease. *Radiology*. 2016 Mar;278(3):792–800.
 61. Sleisenger and Fordtran's gastrointestinal and liver disease : pathophysiology, diagnosis, management [Internet]. [cited 2017 Nov 17]. Available from: <https://www.ncbi.nlm.nih.gov/nlmcatalog/101500948>
 62. Rieder F, Zimmermann EM, Remzi FH, Sandborn WJ. Crohn's disease complicated by strictures: a systematic review. *Gut*. 2013 Jul;62(7):1072–84.
 63. Thorwarth D, Henke G, Müller A-C, Reimold M, Beyer T, Boss A, et al. Simultaneous 68Ga-DOTATOC-PET/MRI for IMRT treatment planning for meningioma: first experience. *Int J Radiat Oncol Biol Phys*. 2011 Sep 1;81(1):277–83.
 64. Nasu K, Kuroki Y, Nawano S, Kuroki S, Tsukamoto T, Yamamoto S, et al. Hepatic metastases: diffusion-weighted sensitivity-encoding versus SPIO-enhanced MR imaging. *Radiology*. 2006 Apr;239(1):122–30.
 65. Padhani AR, Koh D-M, Collins DJ. Whole-body diffusion-weighted MR imaging in cancer: current status and research directions. *Radiology*. 2011 Dec;261(3):700–18.
 66. Bruegel M, Holzappel K, Gaa J, Woertler K, Waldt S, Kiefer B, et al. Characterization of focal liver lesions by ADC measurements using a respiratory triggered diffusion-weighted single-shot echo-planar MR imaging technique. *Eur Radiol*. 2008 Mar;18(3):477–85.
 67. Eiber M, Beer AJ, Holzappel K, Tauber R, Ganter C, Weirich G, et al. Preliminary results for characterization of pelvic lymph nodes in patients with prostate cancer by diffusion-weighted MR-imaging. *Invest Radiol*. 2010 Jan;45(1):15–23.
 68. Fornasa F, Nesoti MV, Bovo C, Bonavina MG. Diffusion-weighted magnetic resonance imaging in the characterization of axillary lymph nodes in patients with breast cancer. *J Magn Reson Imaging*. 2012 Oct;36(4):858–64.

69. Brown G, Richards CJ, Bourne MW, Newcombe RG, Radcliffe AG, Dallimore NS, et al. Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison. *Radiology*. 2003 May;227(2):371–7.
70. De Iaco P, Musto A, Orazi L, Zamagni C, Rosati M, Allegri V, et al. FDG-PET/CT in advanced ovarian cancer staging: value and pitfalls in detecting lesions in different abdominal and pelvic quadrants compared with laparoscopy. *Eur J Radiol*. 2011 Nov;80(2):e98-103.
71. Soussan M, Des Guetz G, Barrau V, Aflalo-Hazan V, Pop G, Mehanna Z, et al. Comparison of FDG-PET/CT and MR with diffusion-weighted imaging for assessing peritoneal carcinomatosis from gastrointestinal malignancy. *Eur Radiol*. 2012 Jul;22(7):1479–87.
72. De Gaetano AM, Calcagni ML, Rufini V, Valenza V, Giordano A, Bonomo L. Imaging of peritoneal carcinomatosis with FDG PET-CT: diagnostic patterns, case examples and pitfalls. *Abdom Imaging*. 2009 Jun;34(3):391–402.
73. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer*. 2009 Jan;45(2):228–47.
74. Kirchner J, Kirchner EM, Goltz JP, Lorenz V-W, Kickuth R. Prevalence of enlarged mediastinal lymph nodes in heavy smokers--a comparative study. *Eur Radiol*. 2011 Aug;21(8):1594–9.
75. Park JM, Kim IY, Kim SW, Lee SM, Kim HG, Kim SY, et al. A comparative study of FDG PET/CT and enhanced multi-detector CT for detecting liver metastasis according to the size and location. *Ann Nucl Med*. 2013 Apr;27(3):217–24.
76. Holalkere N-S, Sahani DV, Blake MA, Halpern EF, Hahn PF, Mueller PR. Characterization of small liver lesions: Added role of MR after MDCT. *J Comput Assist Tomogr*. 2006 Aug;30(4):591–6.
77. Barker DW, Zagoria RJ, Morton KA, Kavanagh PV, Shen P. Evaluation of liver metastases after radiofrequency ablation: utility of 18F-FDG PET and PET/CT. *AJR Am J Roentgenol*. 2005 Apr;184(4):1096–102.
78. Nakai T, Okuyama C, Kubota T, Yamada K, Ushijima Y, Taniike K, et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. *Eur J Nucl Med Mol Imaging*. 2005 Nov;32(11):1253–8.
79. Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. *J Clin Oncol*. 2004 Jul 15;22(14):2942–53.
80. Sugawara Y, Fisher SJ, Zasadny KR, Kison PV, Baker LH, Wahl RL. Preclinical and clinical studies of bone marrow uptake of fluorine-18-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. *J Clin Oncol*. 1998 Jan;16(1):173–80.
81. Even-Sapir E, Metser U, Flusser G, Zuriel L, Kollender Y, Lerman H, et al. Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. *J Nucl Med*. 2004 Feb;45(2):272–8.

82. Damle NA, Bal C, Bandopadhyaya GP, Kumar L, Kumar P, Malhotra A, et al. The role of ¹⁸F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma: a comparison with FDG PET/CT and ^{99m}Tc-MDP bone scan. *Jpn J Radiol.* 2013 Apr;31(4):262–9.
83. Lecouvet FE, El Mouedden J, Collette L, Coche E, Danse E, Jamar F, et al. Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc ^{99m} bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? *Eur Urol.* 2012 Jul;62(1):68–75.
84. Schöder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. *Semin Nucl Med.* 2004 Oct;34(4):274–92.
85. Kim DJ, Kim JH, Ryu YH, Jeon TJ, Yu J-S, Chung J-J. Nodal staging of rectal cancer: high-resolution pelvic MRI versus ¹⁸F-FDGPET/CT. *J Comput Assist Tomogr.* 2011 Oct;35(5):531–4.
86. Kim SH, Choi BI, Han JK, Kim HD, Lee HP, Kang SB, et al. Preoperative staging of uterine cervical carcinoma: comparison of CT and MRI in 99 patients. *J Comput Assist Tomogr.* 1993 Aug;17(4):633–40.
87. Kim DJ, Kim JH, Lim JS, Yu J-S, Chung J-J, Kim M-J, et al. Restaging of Rectal Cancer with MR Imaging after Concurrent Chemotherapy and Radiation Therapy. *Radiographics.* 2010 Mar;30(2):503–16.
88. Stolzmann P, Veit-Haibach P, Chuck N, Rossi C, Frauenfelder T, Alkadhi H, et al. Detection rate, location, and size of pulmonary nodules in trimodality PET/CT-MR: comparison of low-dose CT and Dixon-based MR imaging. *Invest Radiol.* 2013 May;48(5):241–6.